Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...